Lipid CME
CMEABIM MOC

New Oral Options for Diabetic Dyslipidemia Management

Author(s)/Faculty: Christie M Ballantyne, MD; Harold E. Bays, MD, FOMA, FTOS, FACC; Erin D Michos, MD, MHS
Release Date: 6/30/2020Expiration Date: 6/29/2021
Credit Type: CME / ABIM MOCNumber of Credits: 1.5
Content Type: LectureProvider:
Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease (CVD), which is the leading cause of death in the US, claiming over 800,000 lives annually. While many patients with elevated low-density lipoprotein cholesterol (LDL-C) benefit from statin therapy, about 10-30% suffer from statin intolerance or dose-limiting toxicities, which leaves them at risk for adverse cardiovascular events. To address this problem, expert clinicians will conduct an educational activity in conjunction with the 2020 American Diabetes Association conference for internists, endocrinologists, and diabetologists that details the latest therapeutic options for reducing LDL-C in patients with diabetes.